SWKHL— SWK Holdings Corp

Metric	FY2025	FY2024	FY2023	FY2022
Revenues:
Finance receivable interest income, including fees	$38.4M-5.8%	$40.8M+12.2%	$36.3M+2.5%	$35.5M
Pharmaceutical development	$2.2M-40.5%	$3.6M+200.8%	$1.2M-78.1%	$5.5M
Other	$865K+48.1%	$584K+175.5%	$212K-60.6%	$538K
Total revenues	$41.5M-7.8%	$45.0M+19.1%	$37.8M-9.0%	$41.5M
Costs and expenses:
Provision for (benefit from) credit losses	-$924K-107.2%	$12.8M+567.2%	$1.9M-45.2%	$3.5M
Loss on impairment	$641K	—	—	—
Loss on disposal of inventory	$314K	—	—	—
Interest expense	$4.8M+2.4%	$4.7M+153.4%	$1.8M+443.8%	$340K
Pharmaceutical manufacturing, research and development expense	$1.6M-29.6%	$2.2M-35.9%	$3.4M-50.6%	$7.0M
Change in fair value of acquisition-related contingent consideration	$0+100.0%	-$4.9M+22.2%	-$6.3M-221.9%	$5.2M
Depreciation and amortization expense	$40K-97.1%	$1.4M-45.7%	$2.6M-0.8%	$2.6M
General and administrative expense	$14.8M+28.5%	$11.5M+2.3%	$11.2M-13.4%	$13.0M
Income from operations	$20.3M+75.0%	$11.6M-20.9%	$14.7M+47.0%	$10.0M
Other income (expense), net
Unrealized net gain on warrants	$775K-67.8%	$2.4M+4474.5%	-$55K-113.2%	$417K
Net gain on exercise and cancellation of warrants	$0-100.0%	$445K+155.7%	-$799K	—
Loss on sale of assets	-$82K	—	—	—
Gain on sale of business	$1.6M	—	—	—
Net loss on marketable investments	-$384K-44.4%	-$266K	$0	—
Realized gain on early payment of finance receivables	$1.7M+62.3%	$1.1M	$0	—
Gain (loss) on revaluation of finance receivables	-$3.7M-249.4%	$2.5M	$0	—
Realized and unrealized foreign currency transaction gains (losses)	-$71K-111.1%	$641K-21.5%	$817K	—
Income before income tax expense	$20.1M+9.5%	$18.4M+25.7%	$14.6M	—
Income tax expense	$22.6M+363.7%	$4.9M+483.4%	-$1.3M+68.2%	-$4.0M
Net income (loss)	-$2.5M-118.8%	$13.5M-15.1%	$15.9M	—
Net income (loss) per share
Basic (in dollars per share)	-$0.21-119.3%	$1.09-13.5%	$1.26+20.0%	$1.05
Diluted (in dollars per share)	-$0.21-119.4%	$1.08-13.6%	$1.25+19.0%	$1.05
Weighted average shares outstanding
Basic (in shares)	12.2M-1.7%	12.4M-2.2%	12.7M-1.4%	12.8M
Diluted (in shares)	12.2M-2.3%	12.5M-1.9%	12.7M-1.4%	12.9M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 12 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.